Bearish options skew and rising short borrow demand signal caution. Analysts have lifted targets in recent weeks, but insiders sold $4.5M net over 90 days.
Short interest stands at 2.15% of free float as of April 23. Shares short rose 2.6% day-over-day and are up 5.0% over the past month, though the week saw a 2.8% decline. Days to cover sits at 4.4 according to the latest FINRA data. Cost to borrow is minimal at 0.50%, reflecting easy availability. Utilisation hit 3.13%, near its 52-week high of 3.44%, indicating modest but growing borrow demand heading into the print.
The put/call ratio jumped to 0.44 on April 24, well above the 20-day mean of 0.35. The z-score of 2.17 flags elevated hedging activity. The PCR sits in the upper half of its 52-week range (0.17–1.88), suggesting traders are pricing in downside risk around earnings.
Wall Street maintains a constructive stance. The average price target of $85.81 implies 7.5% upside from the $79.80 close. RBC Capital raised its target to $95 on April 24, the highest among recent moves. Wells Fargo lifted to $90 on April 21, and Oppenheimer went to $89 on April 22. All three maintained Outperform-equivalent ratings. JP Morgan downgraded to Neutral in early February but still raised its target to $77, citing valuation after the rally. Benzinga's bull case notes reaffirmed 2025 guidance and sees a 12% SOTP upside with shares trading at 12.0x EV/EBITDA. The bear case warns the planned late-2026 seeds spin-off could create volatility, and competitive pressure from Bayer threatens crop protection margins.
P/E compressed to 21.0x from 21.9x a month ago. EV/EBITDA sits at 12.4x, down slightly over 30 days. CTVA ranks in the 77th percentile on forward EPS growth momentum but only the 4th percentile on earnings surprise, signaling expectations are high but recent beats have been scarce. The dividend score ranks in the 99th percentile, reflecting the stock's 0.96% yield appeal.
Insiders sold $4.53M net over the past 90 days. CEO Charles Magro sold $857K across two February transactions. No material purchases offset the selling. Vanguard and BlackRock remain the largest holders at 12.0% and 8.9%, respectively. FMR added 4.2M shares as of late February, lifting its stake to 3.9%.
CTVA last reported on February 3, 4, and 5, 2026, with multiple announcements clustered around the quarter-end window.
No ORTEX Alpha signals are currently active for CTVA.
See the live data behind this article on ORTEX.
Open CTVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
